Novavax, Inc. (NASDAQ:NVAX) insider Stanley C. Erck acquired 100,000 shares of Novavax stock in a transaction on Thursday, November 9th. The stock was acquired at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the completion of the purchase, the insider now owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Novavax, Inc. (NASDAQ:NVAX) traded down $0.03 during trading hours on Thursday, hitting $1.16. 2,862,300 shares of the company were exchanged, compared to its average volume of 5,936,355. Novavax, Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $1.78. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The business had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.42 million. During the same period last year, the business posted ($0.24) earnings per share. The firm’s quarterly revenue was up 158.5% on a year-over-year basis. research analysts predict that Novavax, Inc. will post -0.63 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insider Buying: Novavax, Inc. (NVAX) Insider Acquires $113,000.00 in Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/16/insider-buying-novavax-inc-nvax-insider-acquires-113000-00-in-stock.html.
Several large investors have recently modified their holdings of NVAX. Bank of New York Mellon Corp raised its holdings in shares of Novavax by 0.9% during the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock worth $1,555,000 after acquiring an additional 10,347 shares during the period. American International Group Inc. increased its stake in Novavax by 7.1% in the 1st quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,965 shares during the last quarter. Vanguard Group Inc. increased its stake in Novavax by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock valued at $27,752,000 after buying an additional 938,581 shares during the last quarter. Geode Capital Management LLC increased its stake in Novavax by 18.3% in the 1st quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock valued at $3,073,000 after buying an additional 371,295 shares during the last quarter. Finally, KCG Holdings Inc. increased its stake in Novavax by 161.0% in the 1st quarter. KCG Holdings Inc. now owns 178,797 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 110,292 shares during the last quarter. Institutional investors and hedge funds own 38.87% of the company’s stock.
NVAX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price target on shares of Novavax in a research report on Wednesday, November 8th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Seaport Global Securities reissued a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Finally, Chardan Capital reissued a “neutral” rating and set a $1.50 price target on shares of Novavax in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Novavax currently has a consensus rating of “Hold” and a consensus price target of $3.12.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.